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Abstract
Background—Chronic Kidney Disease (CKD) is associated with alterations in phosphorus 
excretion, and increases in fibroblast growth factor (FGF23) and parathyroid hormone (PTH). 
Plant protein based phytate bound phosphorus, is less bioavailable than that from animal sources. 
Our prior one week study showed that a nearly 100% plant protein based diet benefits mineral 
metabolism in CKD; however this diet may not be acceptable to patients. Here we hypothesize 
that a diet containing 70% protein from plants has similar efficacy and is tolerated by CKD 
patients.
Methods—Thirteen subjects with CKD 3-4 received an omnivore diet containing 70% protein 
from plants for 4 weeks. The primary outcome was change in 24 hour urine phosphorus. 
Secondary outcomes were changes in serum phosphorus, FGF23, PTH, urine sodium excretion, 
grip strength and fat free mass. Repeated measures analysis of variance (ANOVA) was used to 
test differences in parameters over the 4 weeks.
Results—Mean age of subjects was 54.8 years. Median eGFR was 26 (IQR 14.7) ml/min/
1.73m2. Over the 4 week period, urine phosphorus significantly decreased by 215±232 mg/day 
(p<0.001). No significant changes in serum FGF23, phosphorus or PTH were noted. Urine sodium 
and titratable acid decreased significantly on the diet. Hand grip strength and fat-free mass did not 
change. There were two hyperkalemia events both 5.8 meq/l, corrected by food substitutions. No 
other adverse events were observed.
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Conclusions—A 70% plant protein diet is safe, tolerated, and efficacious in lowering urine 
phosphorus excretion and may be an alternative to phosphate binders.
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Introduction
Disturbances in urinary excretion of phosphorus, reflective of its intestinal absorption, 
occurs early in CKD and changes in FGF23 and PTH in CKD are likely compensatory 
responses to this decrease [1]. In the general population, increased dietary phosphorus intake 
is associated with left ventricular hypertrophy [2], a nine fold increased risk of fractures [3] 
and increased mortality [4]. In CKD, hyperphosphatemia is associated with increased 
cardiovascular disease [5, 6] and fractures [7, 8] resulting in decreased quality of life and 
survival in CKD.
In the western diet, phosphorus is ingested primarily from animal and dairy foods and as 
preservatives or additives in processed foods. Since foods high in phosphorus are high in 
protein, guidelines suggest adherence to foods with a phosphate/protein ratio of 10-12 mg/g, 
which can be difficult for patients given the lack of phosphorus information on food labels 
[9]. Our group found that a grain, compared to meat/casein diet reduced phosphorus and 
PTH in a rodent model of CKD-MBD [10]. We hypothesized that this was due to binding of 
phosphorus to phytate in the grains, reducing bioavailability. We then examined the efficacy 
of one week of a nearly 100% plant protein based diet versus a diet with 80% animal protein 
in patients with advanced CKD (mean eGFR of 32 ml/min/1.73m2) in a crossover trial, 
demonstrating lower fasting serum phosphorus and FGF23, and decreased urinary 
phosphorus excretion on the plant-based diet [11].
However, adherence to a 100% protein from plants diet is difficult in those who are not self-
declared vegans [12], and thus a diet that allows 30% animal protein in patients with 
advanced CKD may be better tolerated. We therefore tested the hypothesis that a diet 
consisting of 70% protein from plants and 30% protein from animals (meat, dairy, eggs) 
would lower urinary phosphorus excretion and FGF23 and whether this effect would be 
sustained over a 4 week period. We assessed whether there were adverse effects on 
potassium and blood sugars and monitored for unintentional weight loss. There are reports 
of correlations of skeletal muscle mass with animal protein content in diets [13, 14] and 
therefore we monitored fat free mass and hand-grip strength.
Subjects and Methods
The study was 6 weeks long, with a pre-study phase of 1-2 weeks and study diet phase of 4 
weeks. Subjects were recruited from clinics managed by Indiana University Nephrology. 
Inclusion criteria were 1) Age > 18 years, 2) eGFR 15-60 ml/min/1.73m2 and determined to 
be chronic in etiology per primary nephrologist, 3) medically stable, 4) able to give 
informed consent and 5) able to read and comprehend diet instructions. Exclusion criteria 
were 1) uncontrolled high blood pressure defined by primary nephrologist, 2) acute kidney 
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injury, 3) anticipated dialysis within the next 6 months, 4) proteinuria greater than 10 g or 
with an increase by 50% in the past year, 5) prescribed phosphate binders, 6) prescribed 
calcitriol or its analogs in the previous 30 days, 7) unable to tolerate planned diets, or 8) 
cirrhosis. All study procedures were conducted in accordance with the Declaration of 
Helsinki and documents were approved by the Indiana University School of Medicine 
Institutional Review Board.
Figure 1 shows the study design. The pre-study phase was two weeks during which the 
subjects were asked to consume their usual diet and collect two 24 hour urines and undergo 
blood tests, which were averaged to yield baseline values for urine and blood, respectively. 
The baseline dietary intake was based on 5 days of food records that included at least one 
weekend day and one weekday. Baseline dietary protein source intake was calculated using 
Minnesota Nutrition Data System for Research (NDSR, version 2011: http://
www.ncc.umn.edu/products/ndsr.html) by study dietitian. The dietary records were 
reviewed with study personnel and a food recall performed as needed for clarification. 
During the pre-study phase, subjects also discussed food preferences, dislikes, allergies and 
intolerances with the study dietitian to optimize the standardized prepared study diets for the 
intervention period. The study diet period was 4 weeks in duration, with 7 study visits to 
pick up prepared food, determine compliance, assess adverse events and provide education. 
End point assessments were done at 2 and 4 weeks of the study period (Figure 1). All foods 
and beverages (except water) were provided and prepared by the Indiana Clinical Research 
Institute (ICRC) kitchen. Subjects were counseled by study dietitian to consume provided 
foods and beverages. Subject compliance was assessed with the use of “menu checklists” 
where subjects marked all food items consumed on a list of provided food items.
All 24 hour urine collections were analyzed for phosphorus, sodium, potassium, creatinine, 
urea nitrogen, sulfates, pH, citrate, ammonium and calcium by commercially available 
assays (http://www.litholink.com). Blood draws were performed on the day of return of all 
24hr urine collections and analyzed for basic metabolic profile, calcium, phosphorus and 
albumin using the hospital laboratory. Blood was collected, stored at -80°C and batch 
analyzed for C-terminal FGF23 (Immunotopics, San Clemente, CA) and intact PTH 
(ALPCO, Salem, NH).
Subjects underwent bioelectrical impedance (BIA) testing using a body analyzer (Tanita 
Scale UM-061) and hand grip strength measurements (Northern Coast Medical Precision 
Instruments, Gilroy, CA). Each reading for both measures was performed in duplicates and 
the average measure used. Diabetic subjects were asked to maintain blood glucose and 
insulin logs and bring these to study visits to adjust as needed.
Study diets were designed to deliver 0.8-.9 mg/kg protein (0.84/kg protein mean), 0.8-1.3g 
of P, ∼700-1000 mg of calcium, 2-4 g sodium (2.2g mean), and 2-3 g potassium as 
recommended for CKD patients [9]. The protein source was 70% from plant sources and the 
diets repeated every 4 days. Nutrient and phytate content of foods used in study were 
obtained from the University of Minnesota Nutrition Data System for Research and food 
labels. Diets were ashed to confirm composition and only minor adjustments to the menu 
were required. Food was purchased from local grocery stores using predominately 
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preservative free food if available to maximize accuracy of the nutrient database assessment. 
Table 1 shows a sample menu of study diet for 4 days. Subject's energy requirements were 
estimated using self-reported physical activity levels and the sex-specific equation published 
by the Institute of Medicine [15]. Table 2 indicates the final diet composition. . During the 4 
weeks additional dietary modifications were done only for safety reasons, i.e.a serum 
potassium≥5.8 meq/l. (hyperkalemia).
Statistical analyses
We determined that a sample size of 5 subjects would have given us 80% power using 
paired t test and an alpha of 0.05 to detect a difference of 0.36± 0.21 g/24hrs in urine 
phosphorus excretion, the achieved difference in urine phosphorus excretion in the nearly 
100% protein from plants diet in a one week trial[11]. However, given we did not have prior 
data for the effect of a 70% protein from plants diet on urine phosphorus excretion, we 
targeted a final n=12, the number of suggested subjects for a pilot trial [16], recruiting 16 to 
allow for drop outs.
Paired t-tests or signed rank tests were used to calculate comparisons between baseline study 
measures (average of 2 pre-study blood and urine collections) and the average of values at 
week 2 and 4. Repeated measures ANOVA and ANOVA on ranks were also performed to 
compare the changes in each study parameter in blood and urine over time, using data from 
the 2 and 4 week collections Results are expressed as mean ± SD, or as median (25th, 75th 
percentile) if non-normally distributed. A significance level of α = 0.05 was used for 
statistical tests. Analyses were performed using Sigmaplot (SigmaPlot, Chicago, IL).
Results
Thirteen subjects, 6 males and 7 females, aged 54.8 +/- 13 years completed the study. Of 
these subjects 7 were Caucasian and 4 were diabetic. Sixteen subjects consented, but two 
dropped out due to transportation issues and one subject because of food dislikes. Table 3 
shows the characteristics for the 13 participants who completed the study. Based on the 
nutrient analysis of 5 days of food records in the pre-study period, subjects had a mean 
intake of 35±0.1 % of plant based protein on their “usual” or pre-study diet. This compares 
to 70±0.5% plant based protein in the study period (p <0.001). The change in phytate was 
also significant from a mean of 532±416 mg per day in the pre-study period to 1333±215 
mg of phytate per day on the study diet (p<0.001). There was an overall median 95% 
compliance with the prescribed diets, with a median compliance of 94% in the first 2 weeks 
and 97% in the later 2 weeks, though 3 subjects had a drop in compliance between these 
time points (Table 3).
The primary end point for the study was urinary phosphorus excretion which decreased from 
830 ± 244 mg/day (range 0.4 to 1.2 g/day) by 28% to an average of 597 ± 233 mg/
day(p<0.001) by paired t-tests. Figure 2 shows the change in urine phosphorus excretion by 
subject. There was no significant difference in % diet compliance between the 6 subjects 
who had an increase in urine phosphorus between the 2 week and 4 week visit and the others 
(95 versus 98%, p=0.5). Urine phosphorus decreased significantly over time (by 30% at 2 
weeks and 26% at 4 weeks from baseline), with no significant difference between the 2 and 
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4 week measure. (See Table 4 for repeated measures analysis and values for urine 
parameters). Mean urine creatinine excretion dropped significantly during the study period 
(p=0.038), however this did not alter creatinine clearance. Normalizing the urinary 
phosphorus excretion to the urine creatinine excretion did not alter the results. The titratable 
acid and urinary ammonium excretion decreased significantly (p=0.003 and 0.002 
respectively), although changes in urine pH were not significant (p=0.2). Urine sodium 
excretion significantly decreased.
The results of the blood parameters are shown in Table 5. There was no significant decrease 
in blood measures over the 4 week period, except a drop in serum creatinine of 0.15 ± 0.21 
mg/dl (a 5.8% decrease) over the 4 weeks (p=0.04). FGF23 level decreased by an average of 
12% in the study period but this was not statistically significant. When either the outlier 
(Figure 3), or the patient who was non-compliant (Subject 7) were excluded, the drop was 
30% but this still failed to reach significance. There were a total of 2 incidences of 
potassium of 5.8 meq/L, both of these measures were in the same subject, with a known type 
IV RTA, which required modifying the plant protein source from raw edamame (482mg of 
potassium/100g) the highest potassium content among all plant sources (National Database 
for Standard Reference (USDA Release 26) to fried tofu. To minimize the effect of diurnal 
variation, care was taken to draw blood at a similar time of day (mean within patient 
variability for blood draws was 91 ± 146 minutes).
Subjects experienced a weight loss of 0.8 ± 1.3 kg in the 4 weeks (Table 5, p = 0.025), 
although the free fat mass percentage or hand grip strength was not changed significantly. 
Blood pressure decreased in 8 subjects, though only 1 subject was able to reduce blood 
pressure medications. Mean diastolic blood pressures dropped from 78±12 pre-study to 
72±8.6 mm of Hg (p=0.08) on study diet, while mean systolic blood pressures remained 
stable at 135±17 mm of Hg pre-study to 135 ±13 mm of Hg (p=0.9) on study diet. Insulin 
doses were reduced in 3 out of 4 diabetic subjects.
Discussion
The present study demonstrated the efficacy of changing from a 65% animal protein diet to a 
70% plant protein diet in lowering urine phosphorus in subjects with stage 3-4 CKD. We 
observed a significant 28% reduction in urinary phosphorus excretion which was sustained 
over a period of 4 weeks. This reduction is less than the 46% decrease in urine phosphorus 
excretion on a 100% plant diet consumed for one week [11] however, it was less restrictive 
for patients and we would hypothesize that it would be easier to maintain. In this study we 
did not compare the utility of a plant based diet with phosphate binders, however the effect 
of a 70% plant protein diet on urine phosphorus excretion appears equivalent to that of 
phosphorus binders. In a randomized controlled trial of 148 patients with mean eGFR of 32 
ml/min and normophosphatemia, similar to subjects in the present study, the effect of 5.9 g/d 
calcium acetate (1.5 g elemental calcium), 2.7 g/d lanthanum carbonate, and 6.3 g/d 
sevelamer carbonate was a 22% decrease in urine phosphorus excretion [17]. This high pill 
burden with administration of phosphorus binders is not well tolerated by most patients, and 
can lead to poor quality of life [18]. The diet was well tolerated and subjects indicated the 
diet was highly palatable and food choices were more varied than expected. The present 
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study suggests that a 70% plant protein diet, allowing one meal per day that contains meat, 
approximately one serving of dairy per day, and an egg every other day would effectively 
lower urinary phosphorus excretion to the same magnitude as high dose phosphorus binders. 
A future randomized trial comparing plant based diets versus binders would be informative 
to guide clinical care.
The goal of reducing intestinal phosphorus absorption and therefore urinary excretion is to 
reduce the stimulus for a rise in FGF23 and/or PTH. Balance studies at this stage of CKD 
have demonstrated neutral phosphorus balance [19], but that neutrality is believed due to the 
compensatory response of the phosphaturic hormones FGF23 and PTH. In the previous short 
term cross over study using a 100% plant based diet, there was a significant reduction in 
FGF23 but no effect on PTH [11]. In contrast, in the present study despite elevated levels of 
FGF23 at baseline, we were unable to detect a significant decrease in these phosphaturic 
hormones, although there was a 12% non-significant reduction in FGF23. Studies have not 
consistently reported decreases in FGF23 and PTH with decreased phosphorus absorption in 
response to diet or binders. In the Chronic Renal Insufficiency Cohort [20], higher plant 
protein intake was associated with lower FGF23 levels (p=0.05). However a higher percent 
plant diet was not associated with decreased urine phosphorus excretion when adjusted for 
protein intake [21]. A randomized 2×2 factorial trial of 16 normophosphtemic CKD patients 
assigned to high and low phosphorus diets with and without lanthanum, showed large 
reductions in urine phosphorus excretion but no significant changes in blood levels of 
FGF23, PTH or phosphorus [22]. In the study of binders in normophosphatemic patients by 
Block et al, despite the 22% drop in urine phosphorus, overall FGF23 levels did not decline 
when comparing active treatment versus placebo [17]. However, the response of FGF23 did 
vary by binder type: a decrease was observed with sevelamer but an increase with calcium 
acetate and no change with Lanthanum [17]. In a smaller study of 40 CKD subjects with 
normal phosphorus levels that were randomized to binders, FGF23 and serum phosphorus 
decreased only in the sevalemer arm, though urine phosphorus excretion decreased in both 
calcium and sevalemer arms [23]. These studies emphasize the complexity of FGF23 
regulation. Importantly, hypercalcemia or elevated calcium load, calcitriol, and PTH all 
stimulate FGF23 secretion [10, 24]. The role of dietary phosphorus on FGF23 may, in fact 
be indirect, and mediated by these factors [25] [26]. Further, serum phosphorus has a diurnal 
variation, with a nadir between 8-12 AM [11], as does PTH [27] [28], which could explain 
why we and others failed to detect a relationship with phosphorus intake, although in general 
labs were drawn at the same time for each patient. These inconsistent data indicate that 
FGF23 needs to be studied more conclusively in future studies.
CKD patients are advised to eat a low protein diet although studies directly testing the 
hypothesis of a protective effect demonstrate conflicting results [29]. One reason for this 
may be because protein source is as important as protein quantity due to the inherent 
differences in the phosphorus content and bioavailability of phosphorus in protein. There is 
also concern of adverse effects of protein restriction as protein is a key regulator of muscle 
metabolism, with protein malnutrition leading to sarcopenia or loss of skeletal muscle in 
patients with kidney disease [30]. CKD patients have more sarcopenia and frailty compared 
to those in the age-matched general population, with decreased skeletal muscle strength and 
walking speed [31]. To confirm no adverse consequences of the change in protein source in 
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the present study, we evaluated hand grip strength, a validated measure of sarcopenia [32] 
and did not observe any decrement in serial assessments. Similarly, fat mass and total body 
water did not change. This suggests safety of this dietary approach although longer studies 
are needed. For example, a prior study of fruits and vegetables in advanced CKD showed an 
improvement in lean mass evaluated after 1 year [33].
There was a decrease in urinary creatinine excretion with the 70% protein from plants diet in 
the present study and a lower serum creatinine, however, calculated creatinine clearance was 
unchanged. The lack of an objective loss in skeletal muscle strength or in fat free mass 
percentage is reassuring and argues against muscle degradation as a cause of the decrease in 
serum creatinine or 24hr creatinine excretion. Cooked meat meals have been shown to 
increase the serum creatinine [34] and thus may explain these observations.
Similar to the Dietary Approaches to Stop Hypertension (DASH) diet with increased fruits 
and vegetables, limiting the quantity of meat and dairy protein in this diet had beneficial 
effects on acidosis. Urine ammonium excretion and the titratable acid in the urine decreased 
significantly by 4 weeks. We did not detect a significant change in serum bicarbonate but 
the values were normal at baseline, and the study was likely too short in duration to show a 
marked improvement. Similar to the DASH diet, there was also a marked decrease in urine 
sodium excretion and the majority of patients had a drop in their blood pressure, an added 
benefit of avoidance of processed foods. We explicitly avoided using processed foods that 
contained phosphorus based additives (the majority of which are sodium phosphate) as this 
is an unmeasurable and inconsistent phosphorus source.
Our study has several strengths. We used rigorously controlled study diets, multiple markers 
of compliance and frequent visits. We were able to analyze the results of following a 
“prepared” diet instead of a “prescribed” diet since we administered all the food and 
beverages eaten. The menu was very comprehensive and provided the recommended renal 
diet. Menu samples were ashed at the start of the study to ensure there were was relative 
good agreement between diet designed using nutritional databases and the actual phosphorus 
content, as dependence on nutritional databases for study design may underestimate actual 
phosphorus in foods up to 350mg/day [35]. We found good agreement, and the errors in 
nutritional database likely reflect phosphorus containing additives, which we purposely 
avoided in these menus. The use of such processed or prepared foods would likely contain 
different amount of phosphorus, as would plant based diets prepared in different seasons 
with grains from different regions. Whether such differences would alter urine phosphorus 
excretion or serum levels of FGF23 and PTH is not known. Finally, our study is limited by 
the small sample size, although the population was diverse and thus the results are likely 
generalizable.
Conclusion
The study demonstrated that converting from a predominant meat based diet to a diet 
composed of 70% protein from plants is efficacious in decreasing dietary phosphorus 
excretion, is palatable for patients and safe. One of the advantages of our study diet of 70% 
protein from plants was increased adherence by subjects who were predominant meat eaters 
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at the start of the study. With administration of ready-to-eat food, there was near complete 
compliance. Longer studies are required to see if the benefits on mineral metabolism, blood 
pressure and acid excretion results in benefits in cardiovascular and musculoskeletal health 
and quality of life in CKD patients.
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Figure 1. 
Overview of Study, with key study procedures on the right, and their timing represented by 
an X. There were a total of 7 visits in the 0 to 4 week “study diet” period for pick-up of 
prepared foods, including the 3 visits with end point assessments.
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Figure 2. 
Twenty-four hour Urine P excretion for each of the 13 subjects. There are 3 bars per subject, 
depicting the pre-study urine P excretion, on 2 weeks of study diet and on 4 weeks of study 
diet.
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Figure 3. 
Changes in FGF23 with diet in all subjects (A) and with outlier excluded (B). Each line 
represents one subject. The outlier excluded had a FGF23>500Ru/ml
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Table 1
Sample Week Menu for 4 week Study Diet
Day 1 Day 2 Day 3 Day 4
Breakfast
Mixed Fruit Pancakes with Syrup 
& Margarine Orange Juice 
Coffee*
Breakfast
Banana Fresh Egg Soft 
Bagel with Margarine & 
Jam Grape Juice Coffee*
Breakfast
Fresh Grapes Kashi Go Lean Crunch 
with 2% Milk Cinnamon Bread with 
Margarine Pineapple Orange Juice 
Coffee*
Breakfast
Fresh Mandarin Orange 
Cheese Omelet Hashbrown 
Potatoes Whole Wheat Toast 
with Margarine & Jam Apple 
Juice Coffee*
Lunch
Peanut Butter & Jelly on Whole 
Wheat Bread Unsalted Pretzels 
Fresh Baby Carrots & Celery 
Sticks Cucumber Dill Dip Diced 
Pears
Lunch
Caesar Salad with Croutons 
Flatbread Turkey Sausage 
Pizza Supreme Fresh Apple 
7-Up
Lunch
Nachos Supreme (Vegetarian Taco 
Meat, Black Beans, Cheese, Salsa, 
Sour Cream & Guacamole) Mandarin 
Oranges in Orange Gelatin
Lunch
Cheeseburger Slider 
Ketchup & Mustard Potato 
Chips Watermelon Brownie 
Bites 7-Up
Snack
Lorna Doone Cookies 2% Milk
Snack
Granola Bar Crystal Light
Snack
Pita Chips 7-Up
Snack
Snack Mix Crystal Light
Dinner
Garden Salad (Carrots/Red 
Cabbage/Tomatoes) with Italian 
Dressing Spaghetti & Turkey 
Meatsauce Fresh Broccoli w/
Margarine French Roll Angel 
Food Cake with Strawberries 
Water or Iced Tea*
Dinner
Meatless Salisbury Steak 
with Mushroom Gravy 
Oven Potato Wedges Green 
Beans w/Margarine French 
Roll w/Margarine Soy 
Pudding Water or Iced Tea*
Dinner
BBQ Pulled Pork Coleslaw Corn w/
Margarine Dinner Roll w/Margarine 
Peaches Water or Iced Tea*
Dinner
Asian Vegetarian Stirfry with 
Edamame White Rice 
Pineapple Tidbits Water or 
Iced Tea*
Snack
Cheese & Crackers 7-Up
Snack
Oreo Cookies 2% Milk
Snack
Popcorn Crystal Light
Snack
Peanut Butter Crackers 
Crystal Light
Animal sources of protein are in bold
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